(1R,9R)-11-(cyclopropylmethyl)-4-methoxy-11-azatetracyclo[7.4.4.01,9.02,7]heptadeca-2(7),3,5-trien-15-one | 1043876-62-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (1R,9R)-11-(cyclopropylmethyl)-4-methoxy-11-azatetracyclo[7.4.4.01,9.02,7]heptadeca-2(7),3,5-trien-15-one
• CAS: 1043876-62-5
• 化学式: C₂₁H₂₇NO₂
• 分子量: 325.451
• InChiKey: OXIADTGGXFQARM-LEWJYISDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1R,9R)-11-(cyclopropylmethyl)-4-methoxy-11-azatetracyclo[7.4.4.01,9.02,7]heptadeca-2(7),3,5-trien-15-one 在 sodium tetrahydroborate 、 正丁基锂 、 sodium hydride 、 magnesium 、 三氯氧磷 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 为溶剂， 生成 (2S,4aS,9aR)-11-(cyclopropylmethyl)-6-methoxy-N-phenyl-1,2,3,4-tetrahydro-9H-4a,9a-(ethanoiminomethano)fluorene-2-carboxamide
  参考文献：
  名称：

  Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology. Part 2: Propellane derivatives with an amide side chain

  摘要：

  We designed and synthesized propellane derivatives with a 6- or 7-amide side chain on the basis of the active conformation of the kappa selective agonist nalfurafine. The 6-amides showed high affinities for the kappa receptor, and one of the 6 beta-amides showed higher kappa selectivity than nalfurafine. On the other hand, although the affinities of the 7-amides decreased compared to the 6-amides, some 7 alpha-amides showed the highest selectivities for the kappa receptor among the tested compounds. The affinities of 7 beta-isomers were extremely low, which was postulated to result from the shielding effect of the 7 beta-amide side chain against the lone electron pair on the 17-nitrogen. This is the first conformational information about the 7-amide side chain in propellane derivatives. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.082
• 作为产物：
  描述：

  (1'R,9'R)-11'-(cyclopropylmethyl)-4'-methoxyspiro[1,3-dioxolane-2,15'-11-azatetracyclo[7.4.4.01,9.02,7]heptadeca-2(7),3,5-triene] 在 盐酸 作用下， 以 水 为溶剂， 反应 0.17h， 以95%的产率得到(1R,9R)-11-(cyclopropylmethyl)-4-methoxy-11-azatetracyclo[7.4.4.01,9.02,7]heptadeca-2(7),3,5-trien-15-one
  参考文献：
  名称：

  具有丙炔骨架的新型阿片样物质衍生物的合成及其药理作用：第1部分

  摘要：

  没有4,5-环氧环的17-环丙基甲基吗啡喃衍生物比具有4,5-环氧环的衍生物具有更大的κ选择性，这使我们提出了一个可行的假设：由A和B环组成的平面的位置会影响阿片受体类型的选择性，扭转角C11–C12–C13–C14的减小可以改善κ选择性。与我们的假设一致，具有N-环丙基甲基丙炔结构的KNT-42 （其A和B环固定在大约0°的扭转角中）显示κ选择性激动剂活性。

  DOI：

  10.1016/j.bmcl.2011.04.147

文献信息

• Synthesis and opioid receptor activity of indolopropellanes
  作者：Fuying Li、Linghuan Gaob、Chenlei Yin、Jie Chen、Jinggen Liu、Xin Xie、Ao Zhang

  DOI：10.1016/j.bmcl.2009.06.093

  日期：2009.8

  displayed moderate binding affinity and selectivity at the μ receptor, with compound 7b showing the highest affinity at this receptor with a Ki value of 40 nM, and 6- and 25-fold selectivity against δ and κ receptors, respectively. Function assays showed that indolopropellanes 7b and 7c possessed full agonistic activity at all the opioid receptors indicating a different interaction model existed.

  通过3-甲氧基-N-甲基-14-羟基吗啡喃-6-one 12的N-去甲基化，然后进行N-重烷基化，还原和Fischer吲哚环化，获得了一系列骨架重排的吲哚吗啡喃7a-d。通过X射线分析证实了该新型骨架的结构。这些新的吲哚在μ受体上表现出中等的结合亲和力和选择性，化合物7b在该受体上显示出最高亲和力，其K i值为40 nM，对δ和κ受体的选择性分别为6倍和25倍。功能测定表明吲哚丙二酮7b和7c 在所有阿片样物质受体上都具有完全激动作用，表明存在不同的相互作用模型。
• [EN] PROPELLANE-BASED COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR MODULATORS<br/>[FR] COMPOSÉS À BASE DE PROPELLANE ET UTILISATION DE CES DERNIERS EN QUALITÉ DE MODULATEURS DE RÉCEPTEURS D'OPIOÏDES
  申请人：PURDUE PHARMA LP

  公开号：WO2015097546A1

  公开（公告）日：2015-07-02

  The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R'-R3 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I) to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

  该申请涉及公式（I）的化合物及其药学上可接受的盐和溶剂化物，其中R'-R3的定义如规范中所述。该发明还涉及使用公式（I）的化合物来治疗对一种或多种阿片受体调节敏感的疾病，或作为合成中间体。本发明的某些化合物特别适用于治疗疼痛。
• Synthesis of a Stable Iminium Salt and Propellane Derivatives
  作者：Hiroshi Nagase、Naoshi Yamamoto、Toru Nemoto、Kenji Yoza、Kenshu Kamiya、Shuichi Hirono、Shinobu Momen、Naoki Izumimoto、Ko Hasebe、Hidenori Mochizuki、Hideaki Fujii

  DOI：10.1021/jo801276z

  日期：2008.10.17

  The treatment of morphinan I with NaH and MsCl provided very stable iminium salt 7 possessing propellane skeleton. One of the synthesized iminium salts 7, isobutyl derivative 7b, was crystallized and its structure was determined by X-ray crystallography. The natural bond orbital analysis suggested that the stability of the iminium should result from the stereoelectronic effect (hyperconjugation) attributed to their own structures.
• Design and synthesis of quinolinopropellane derivatives with selective δ opioid receptor agonism
  作者：Hiroshi Nagase、Ryo Nakajima、Naoshi Yamamoto、Shigeto Hirayama、Takashi Iwai、Toru Nemoto、Hiroaki Gouda、Shuichi Hirono、Hideaki Fujii

  DOI：10.1016/j.bmcl.2014.04.098

  日期：2014.7

  Indolopropellane 2 was reported to show almost no binding affinity to the delta opioid receptor (DOR) in spite of the fact that 2 has both the propellane fundamental skeleton (message part) with binding ability to the opioid receptors and a possible DOR address structure (indole moiety). We developed the working hypothesis that almost no binding affinity of 2 to the DOR would be derived from its possibly stable bent conformer. To enable the propellane skeleton to adopt an extended conformation which would reasonably interact with the DOR, quinolinopropellanes 3a-d were designed which had an additional pharmacophore, quinoline nitrogen. The calculated binding free energies of ligand-DOR complexes strongly supported our working hypothesis. The synthesized quinolinopropellane 3a was a selective DOR full agonist, confirming our working hypothesis and the results of in silico investigation. (C) 2014 Elsevier Ltd. All rights reserved.
• PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150183787A1

  公开（公告）日：2015-07-02

  The application is directed to compounds of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R 1 -R 5 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.